Stocks · News reference
Preclinical Data Poster Highlights Dual Estrogen Receptor and PKC-β/AKT Pathway Modulation as a Potential Therapeutic Strategy for Estrogen-Driven Pathology in McCune-Albright syndromeSEATTLE, July 21, 2026 /PRNewswire/
Reference Details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
Atossa Therapeutics (NASDAQ:ATOS) reported quarterly losses of $(0.95) per share which beat the analyst consensus estimate of $(1.02) by 6.86 percent. This is a 171.43 percent decrease over losses of $(0.35) per share
Filed: 2026-08-07 AccNo: 0001193125-26-339292 Size: 542 KB Item 2.02: Results of Operations and Financial Condition Item 9.01: Financial Statements and Exhibits
Peer-reviewed preclinical study published in npj Breast Cancer identifies new chemical entities with activity in ESR1-mutant modelsFindings suggest potential for combination with abemaciclibSEATTLE, July 28, 2026